Impact of positive peri-stent vascular remodeling after sirolimus-eluting and paclitaxel-eluting stent implantation on 5-year clinical outcomes: Intravascular ultrasound analysis from the poststent optimal stent Expansion Trial multicenter randomized Trial

Circulation Journal

Volumn 76, Issue 5, 2012, Pages 1102-1108

  Kang, Ki Woon ^a   Ko, Young Guk ^b   Shin, Dong Ho ^b   Kim, Jung Sun ^b   Kim, Byeong Keuk ^b   Choi, Donghoon ^b   Hong, Myeong Ki ^b   Kang, Woong Chol ^c   Ahn, Taehoon ^c   Jeon, Dong Woon ^d   Yang, Joo Young ^d   Jang, Yangsoo ^b  

^a Eulji University   (South Korea)

^b Yonsei University Health System   (South Korea)

^c Gachon University College of Medicine   (South Korea)

^d National Health Insurance Corporation   (South Korea)

Author keywords

Coronary artery disease; Drug eluting stent; Late and very late stent thrombosis; Vascular remodeling

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; PACLITAXEL; RAPAMYCIN;

ADULT; ARTICLE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HUMAN; INTRAVASCULAR ULTRASOUND; LATE ACQUIRED STENT MALAPPOSITION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; POSITIVE PERI-STENT VASCULAR REMODELING; PREVALENCE; PROSPECTIVE STUDY; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK; STENT THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; CORONARY DISEASE; DRUG-ELUTING STENTS; ELASTICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SIROLIMUS; THROMBOSIS;

EID: 84860142259     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1313     Document Type: Article

References (31)

1. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 2008; 359: 1330-1342.
2. Dibra A, Kastrati A, Alfonso F, Seyfarth M, Perez-Vizcayno MJ, Mehilli J, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: Meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49: 616-623.
3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
4. Hong MK. Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113: 414-419.
5. Kang SJ, Mintz GS, Park DW, Lee SW, Kim YH, Lee CW, et al. Late and very late drug-eluting stent malapposition: Serial 2-year quantitative IVUS analysis. Circ Cardiovasc Interv 2010; 3: 335-340.
6. Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, et al. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: An intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation 2010; 122: 1077-1084.
7. Vanderhoeven B, Liem S, Dijkstra J, Bergheanu S, Putter H, Antoni M, et al. Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: Acute and 9-month intravascular ultrasound results of the MISSION! Intervention Study. JACC Cardiovasc Interv 2008; 1: 192-201.
8. van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008; 51: 618-626.
9. Kim JS, Moon JY, Ko YG, Choi D, Jang Y, Kang WC, et al. Intravascular ultrasound evaluation of optimal drug-eluting stent expansion after poststent balloon dilation using a noncompliant balloon versus a semicompliant balloon (from the Poststent Optimal Stent Expansion Trial [POET]). Am J Cardiol 2008; 102: 304-310.
10. Park SM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, et al. Angiographic and intravascular ultrasound follow up of paclitaxel-and sirolimus-eluting stent after poststent high-pressure balloon dilation: From the Poststent Optimal Stent Expansion Trial. Catheter Cardiovasc Interv 2011; 77: 15-21.
11. de Jaegere P, Mudra H, Figulla H, Almagor Y, Doucet S, Penn I, et al. Intravascular ultrasound-guided optimized stent deployment: Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 1998; 19: 1214-1223.
12. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS): A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: 1478-1492.
13. Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: An intravascular ultrasound analysis. Circulation 2003; 108: 2747-2750.
14. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
15. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: Insights from the randomized TAXUS II trial. Circulation 2005; 111: 900-905.
16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
17. Hassan AKM, Bergheanu SC, Stijnen T, van der Hoeven BL, Snoep JD, Plevier JWM, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2010; 31: 1172-1180.
18. Ko YG, Son JW, Park SM, Kim JS, Choi D, Hong MK, et al. Effect of vessel size on lipid content of coronary plaques assessed by integrated backscatter intravascular ultrasound. Circ J 2010; 74: 754-759.
19. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115: 2426-2434.
20. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus-and paclitaxel-eluting stents. J Am Coll Cardiol 2011; 57: 390-398.
21. Nakazawa G, Finn A, John M, Kolodgie F, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100: S36-S44.
22. Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008; 155: 108-113.
23. Sakurai R, Bonneau HN, Honda Y, Fitzgerald PJ. Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. Am J Cardiol 2007; 100: 71M-76M.
24. Rathore S, Terashima M, Habara M, Kinoshita Y, Nasu K, Katoh O, et al. Incomplete stent apposition after coronary stent implantation: Myth or reality? J Interv Cardiol 2009; 22: 341-349.
25. Kim JS, Kim TH, Fan C, Lee JM, Kim W, Ko YG, et al. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J 2010; 74: 320-326.
26. Miyoshi N, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Comparison by optical coherence tomography of paclitaxel-eluting stents with sirolimus-eluting stents implanted in one coronary artery in one procedure: 6-month follow-up. Circ J 2010; 74: 903-908.
27. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004; 109: 701-705.
28. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drugeluting stent thrombosis. Circulation 2009; 120: 391-399.
29. Siqueira DA, Abizaid AA, Costa Jde R, Feres F, Mattos LA, Staico R, et al. Late incomplete apposition after drug-eluting stent implantation: Incidence and potential for adverse clinical outcomes. Eur Heart J 2007; 28: 1304-1309.
30. Hoffmann R, Morice MC, Moses JW, Fitzgerald PJ, Mauri L, Breithardt G, et al. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: Intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart 2008; 94: 322-328.
31. Hong MK, Mintz GS, Lee CW, Park DW, Lee SW, Kim YH, et al. Impact of late drug-eluting stent malapposition on 3-year clinical events. J Am Coll Cardiol 2007; 50: 1515-1516.